MedTrace Logo

A Study of BGB-11417 in Participants With Myeloid Malignancies

NCT04771130 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2026-04-23

No results posted yet for this study

Summary

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

Conditions

Interventions

DRUG

BGB-11417

Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.

DRUG

Azacitidine

Intravenous or subcutaneous administration for 7 days.

DRUG

Posaconazole

Oral administration for 8 days on second cycle only.

DRUG

BGB-11417

Oral administration for 28 days on a 28-day cycle.

DRUG

BGB-11417

Oral administration for 10, 14 or 21 days on a 28-day

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2028-02-08
Completion
2028-02-08
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • France
  • Germany
  • Italy
  • New Zealand
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04771130 on ClinicalTrials.gov